Market closed· · CAD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
Devonian Health Group Inc. ("Devonian" or the "Company") (TSXV: GSD) (OTCQB: DVHGF) is pleased to announce that in connection with an underwritten public offering, it anticipates to list its common shares and warrants offered on the NYSE American LLC with trading expected to commence as early as September 16, 2026 under the symbols "DHGR" and "DHGR WS", respectively, subject to market conditions and final authorization by the NYSE American LLC of the Company's listing application and continued c
Devonian Health Group Inc. ("Devonian" or the "Company") (TSXV: GSD) (OTCQB: DVHGF), a clinical-stage biopharmaceutical company focused on developing innovative therapies targeting fibro-inflammatory diseases, today announced the successful independent validation and integration of key analytical and biological quality-control technologies into the extraction and manufacturing process for Thykamine™, the Company's lead active botanical drug candidate.
Devonian Health Group Inc. ("Devonian" or the "Company") (TSXV: GSD) (OTCQB: DVHGF) is pleased to announce that in connection with an underwritten public offering, it anticipates to list its common shares and warrants offered on the NYSE American LLC with trading expected to commence as early as August 21, 2026 under the symbols "DHGR" and "DHGR WS", respectively, subject to market conditions and final authorization by the NYSE American LLC of the Company's listing application and continued comp
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.